Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Breast Neoplasms 10Neoplasms 6Prostatic Neoplasms 5Anxiety Disorders 5Leukemia 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 3Neoplasms, Plasma Cell 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma 3Fatigue 3Depression 3Colorectal Neoplasms 3Rectal Neoplasms 2Primary Myelofibrosis 2Hodgkin Disease 2Hematologic Neoplasms 2Head and Neck Neoplasms 2Gastrointestinal Stromal Tumors 2Gastrointestinal Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Anus Neoplasms 2cyclopia sequence 1Vulvar Neoplasms 1Vomiting 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1

Interventions

Epoetin Alfa 9Darbepoetin alfa 5epoetin beta 3telapristone acetate 2fludarabine phosphate 2fludarabine 2Cyclophosphamide 2Carboplatin 2Busulfan 2AP 1903 reagent 2ACE-011 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2venetoclax 1vactosertib 1trametinib 1thymoglobulin 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1peginesatide 1palbociclib 1olaparib 1niraparib 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1hematide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Anemia × Surveys and Questionnaires × Clear all
NCT02730884 2020-08-07

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 6 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Splenomegaly, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡